3.2 ︳Treatments and outcomes
Four preBLL patients were initially treated according to B-NHL/ALL
protocols for mature B-cell leukemia from the beginning. Two courses of
rituximab were administered to one of them because of the early
termination of therapy for recurrent intracranial fungal abscess.
One patient received induction treatment according to protocols for
BCP-ALL for 71 days and switched to B-NHL/ALL courses. In three
patients, intensive treatment was followed by ALL-type maintenance
therapy. Relapse occurred in one patient after 5 months since diagnosis,
and the other four patients had maintained completed remission (CR)
until the last follow-up. The other four patients were treated according
to BCP-ALL protocol9, and two of them relapsed after 7
months and 19 months since diagnosis, respectively (Figure 1).